guest ::
| Home > Publications database > Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. |
| Home > Publications database > Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. |
| Journal Article (Review Article) | DKFZ-2021-03066 |
; ; ; ; ;
2017
Taylor & Franics
Abingdon
This record in other databases: 
Please use a persistent id in citations: doi:10.1080/2162402X.2017.1371896
Abstract: The goal of cancer immunotherapy is to establish new or boost pre-existing anticancer immune responses that eradicate malignant cells while generating immunological memory to prevent disease relapse. Over the past few years, immunomodulatory monoclonal antibodies (mAbs) that block co-inhibitory receptors on immune effectors cells - such as cytotoxic T lymphocyte-associated protein 4 (CTLA4), programmed cell death 1 (PDCD1, best known as PD-1) - or their ligands - such as CD274 (best known as PD-L1) - have proven very successful in this sense. As a consequence, many of such immune checkpoint blockers (ICBs) have already entered the clinical practice for various oncological indications. Considerable attention is currently being attracted by a second group of immunomodulatory mAbs, which are conceived to activate co-stimulatory receptors on immune effector cells. Here, we discuss the mechanisms of action of these immunostimulatory mAbs and summarize recent progress in their preclinical and clinical development.
Keyword(s): CD137 ; CD40 ; GITR ; ICOS ; OX40 ; PD-1
; 
; 
; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
